“SFJ has remained a committed and value-added partner post-deal closure. SFJ continues to demonstrate rapid and timely turn-around regarding alliance governance matters. SFJ consistently displays commitment and follow-through at the most senior levels of the organization.”
— Brian Stewart, VP
Alliance Management, Apellis Pharmaceuticals
5 Approvals
5 Approvals
4 Japan Approvals
3 China Approvals
Multiple Asia-Pacific Approvals
SFJ is uniquely positioned to provide at-risk funding, resources and development expertise to execute global Phase 3 trials